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POSNER – SCHLOSSMAN SYNDROME: CASE REPORT
SINDROME DE POSNER - SCHLOSSMAN: REPORTE DE CASO
Diego José Mamani Maquera1,2,a, Nahuel Pantoja Dávalos1,3,b

CLINICAL CASE

ABSTRACT
Introduction: Posner - Schlossman Syndrome (PSS) is a rare disease, more prevalent in men between
20 and 50 years old, characterized by recurrent attacks of anterior uveitis and ocular hypertension.
Clinical case: We report the case of a 42-year-old patient with a single eye. He came to the consultation
presenting decreased visual acuity, photophobia, halos around the lights, and intense pain in his left
eye. The ophthalmological examination revealed inflammatory signs in the anterior segment, elevated
intraocular pressure and damage to the optic nerve. Medical treatment was started with corticosteroids
and topical antiglaucoma drugs, oral acetazolamide and intravenous mannitol, obtaining no response
and it was decided to perform a surgical intervention (Ahmed valve implantation) in the left eye,
subsequently achieving a good clinical evolution and resolution of the case. Conclusion: This report
highlights that the episodic and recurrent nature of SPS requires strict monitoring.
Key words: Posner-Schlossman syndrome; Anterior uveitis; Ocular hypertension (source: MeSH NLM).

RESUMEN
Introducción: El Sindrome de Posner - Schlossman (SPS) es una enfermedad infrecuente, de mayor
prevalencia en hombres de entre 20 a 50 años, que se caracteriza por presentar ataques recurrentes de
uveítis anterior e hipertensión ocular. Caso clínico: Reportamos el caso de un paciente de 42 años, con
ojo único. Acudió a consulta presentando disminución de la agudeza visual, fotofobia, halos alrededor
de las luces y dolor intenso en su ojo izquierdo. Al examen oftalmológico se evidenciaron signos
inflamatorios en segmento anterior, presión intraocular elevada y daño en el nervio óptico. Se inició
tratamiento médico con corticosteroides y antiglaucomatosos tópicos, acetazolamida oral y manitol
endovenoso, no obteniendo respuesta y se optó por realizar una intervención quirúrgica (implante de
válvula de Ahmed) en el ojo izquierdo, logrando posteriormente una buena evolución clínica y resolución
del caso. Conclusión: Este reporte resalta que la naturaleza episódica y recurrente del SPS requiere un
seguimiento estricto.
Palabras clave: Sindrome de Posner - Schlossman; Uveítis anterior; Hipertensión ocular (fuente: DeCS
BIREME).
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INTRODUCCIÓN
Posner-Schlossman
Syndrome
(PSS)
or
glaucomatocyclitic crisis is a rare disease characterized
by recurrent attacks of non-granulomatous anterior
uveitis and elevated intraocular pressure (IOP)
(ocular hypertension). This is frequently classified as
a secondary inflammatory glaucoma(1,2,3).

CLINICAL CASE

PSS main clinical manifestations are elevated IOP and
blurred vision, tending to affect patients between 20
and 50 years old, most often men than women. The
episodes are unilateral, although in 50% of patients
the other eye is involved at some point. Intervals
between attacks vary, but usually lengthen over
time(1,4).
The etiology of PSS has been investigated in some
studies, which indicated that PSS may be associated
with cytomegalovirus (CMV) infection, genetic
susceptibility, inflammatory cytokines, and vascular
endothelial dysfunction. Among these, CMV
infection is considered a vital risk factor for PSS(5,6).
PSS diagnosis is inherently difficult. The subtlety
of some features of low-grade anterior uveitis
and the short-lived nature of each attack makes
it hard to diagnose. PSS must be differentiated
from acute angle-closure glaucoma, primary openangle glaucoma, uveitic glaucoma, and Fuchs
heterochromic iridocyclitis(7).
Treatment for PSS is aimed at controlling
inflammation and elevated IOP. However, some
patients do not respond to corticosteroids or
antiglaucoma medications. In these cases, surgery is
needed to lower the IOP and thus prevent the visual
field defects progression and damage to the optic
nerve(3,8).
This case refers to a patient with a history of SPS
attacks, who initially received maximum antiinflammatory and anti-glaucoma medical treatment,

https://inicib.urp.edu.pe/rfmh/vol21/iss4/21
Pág. 844
DOI: https://doi.org/10.25176/RFMH.v21i4.3902

Mamani D et al

but as there was no response, surgical treatment was
required.

CLINICAL CASE
We present the case of a 42-year-old man
who presented with decreased visual acuity,
photophobia, halos around lights, and severe pain
in his left eye (LE) for 5 days. The patient refers that
these symptoms have been presenting for 4 years
in a mild and transitory way, so he has not required
medication.
As an ophthalmological history, the patient
underwent surgery for ocular trauma in the right
eye (RE) approximately 30 years ago, with poor
subsequent evolution. At ophthalmological
examination, he presents a corrected visual acuity of
no light perception in RE and 20/70 in LE. IOP was 15
mmHg in the RE and 50 mmHg in the LE. In the anterior
segment examination with a slit lamp in the RE, an
extensive corneal opacity of central predominance of
whitish-gray appearance with stromal deposits was
evidenced, which did not allow to see other details of
the anterior segment; n the LE, mild corneal edema
was evidenced, with the presence of fine keratic
precipitates in the middle third and lower 1/3 of the
corneal endothelium, no atrophy or heterochromia
of the iris, anterior chamber reaction: Tyndall and
Flare (1+), wide anterior chamber, lens opacity NO1
NC1 C2 P1, 360 ° cilium-conjunctival injection (Figure
1). At gonioscopy, the RE could not be evaluated due
to corneal opacity, the LE showed an open angle
(Shaffer grade IV). In the fundus examination, the
RE could not be evaluated due to the opacity of the
media, in the LE a papilla with defined edges was
evidenced, excavation of 0.4, with nasal rejection of
the central vessels, with preserved macular shine,
without inflammation signs in the posterior segment
(Figure 2).
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Figure 1. Slit lamp examination reveals fine keratic precipitates in the middle third and lower 1/3 of the

corneal endothelium of the LE. (Source: Medical history.

Figure 2. The fundus examination reveals a papilla with defined edges, a 0.4 excavation, with nasal rejection
of the central vessels. (Source: Medical history).

Visual field exploration was performed with
program 24-2 of the Humphrey visual field
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analyzer, which revealed the presence of a nasal
step in the LE (Figure 3).
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Figure 3. LE visual field, where the presence of a nasal step is evident. (Source: Medical history).
Laboratory tests were requested: complete blood
count (CBC), acute phase reactants, antinuclear
antibodies, rheumatoid factor, toxoplasmosis
serology, serology for cytomegalovirus, serology for
syphilis, serology for HIV, serology for HTLV 1 and 2,
serology for hepatitis, all of which were normal.
Due to all the above, the diagnosis of PosnerSchlossman syndrome is made and medical
treatment with Acetazolamide (250mg) is started.
1 tablet every 8 hours, Brimonidine (0.2%) 1 drop
every 12 hours, Dorzolamide (2%) 1 drop every 8
hours, Timolol (0.5%) 1 drop every 12 hours and
Prednisolone (1%) 1 drop every 4 hours in the LE. It
was reassessed 48 hours after starting the medical
treatment, the patient reported that the symptoms
had not improved, the decrease in IOP to 40 mmHg
and the persistence of inflammatory signs in the
anterior segment of the LE. Mannitol (20%) 250 ml is
added every 8 hours intravenously. A new evaluation
is carried out 5 days after starting medical treatment
and a decrease in IOP to 30 mmHg in LE is observed,
therefore it is evident that there was not an adequate
response to maximum medical treatment.
Faced with this situation, it was decided to place a
drainage device and extract the cataract from the LE.
Surgical treatment is performed by implanting the
Ahmed valve, phacoemulsification, and placement
of an intraocular lens in LE.
In the postoperative period, the IOP was normal,
without any pharmacological medication. A week
after surgical treatment, a visual acuity of 20/25 was
obtained with correctors and an IOP of 10 mmHg
with clinical relief of ocular symptoms in the LE.
The follow-up was carried out initially once a week,
then monthly, IOP remained normal without any
https://inicib.urp.edu.pe/rfmh/vol21/iss4/21
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pharmacological medication for more than 6 months
after surgery, without attacks of PSS.

DISCUSSION
Posner - Schlossman syndrome is a rare disorder, a
form of anterior uveitis with ocular hypertension
and a higher prevalence in men between 20 and 50
years old(9), characteristics that correspond to our
patient, who was 42 years old and presented the
characteristic clinical picture of this disease.
Posner-Schlossman syndrome has some clinical
features of glaucoma and uveitis, such as ocular
hypertension and the presence of retrokeratic
precipitates(10). These inflammatory signs (retrokeratic
precipitates and reaction in the anterior chamber)
and the markedly elevated intraocular pressure were
described in the initial clinical picture presentation
in our patient.
Early diagnosis and proper treatment may lower the
risk of advanced glaucoma. Frequent attacks of ocular
hypertension are particularly dangerous because
they can easily affect vision by causing progressive
visual field defects. Therefore, IOP control is the most
important goal of treatment(1,10).
Initial treatment for PSS is a combination regimen
of anti-inflammatory and anti-glaucoma drugs.
A topical corticosteroid is often successful in
controlling inflammation. Ocular hypertension
usually normalizes with control of inflammation.
Topical β-blockers and / or carbonic anhydrase
inhibitors are the drugs of choice in patients with
PSS. Prostaglandin analogs efficacy in PSS is not
well established. α2-agonists may also represent a
good therapeutic option. If PSS attacks show higher
frequency and IOP fluctuations are significant with
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attacks, surgical intervention may be indicated(10,11).
The most commonly indicated technique is filtering
surgery (Trabeculectomy), especially in patients with
recurrent attacks and IOP peaks, with damage to
the optic nerve and visual field defects(12). Another
technique also used is valve implant drainage
device surgery, which in many studies is considered
the preferred first-line surgery in the treatment
of uveitic glaucomas(13,14). Our patient received
maximum medical treatment, which was insufficient
for IOP control, so a surgical intervention was finally
performed, placing a valved drainage device (Ahmed
valve).

CONCLUSION
Posner-Schlossman syndrome or glaucomatocyclitic
crisis is a rare disease, characterized by recurrent
attacks of anterior uveitis and ocular hypertension.
PSS usually has a good response to medical
treatment, but as observed in the present case, IOP
could not be controlled, so a surgical intervention
was required, achieving a good clinical evolution
after this. The episodic and recurrent nature of PSS
requires close monitoring, therefore, patients with
SPS should have regular evaluation of visual acuity,
visual field, and IOP.
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PSS is known as a self-limited ocular disease with
benign prognosis, but glaucomatous deterioration
of visual function in some patients is increasingly

reported, therefore, early diagnosis and appropriate
treatment of SPS could decrease the risk of
progression to advanced glaucoma(15,16).
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